EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipoprotein (a), Inflammation, and Atherosclerosis

Stefania Angela Di Fusco iD, Aldo Pietro Maggioni iD, Pietro Scicchitano iD, Marco Zuin, Emilia D'Elia iD, Furio Colivicchi iD

Journal of Clinical Medicine · 27.03.2023 · 12 (7) · 2529

DOI: 10.3390/jcm12072529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.03.2023. Verfasst von Stefania Angela Di Fusco und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Rehabilitation Unit, San Filippo Neri Hospital, ASL Rome 1, 00135 Rome, Italy. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growing evidence has shown that high levels of lipoprotein (a) (Lp(a)) and chronic inflammation may be responsible for the residual risk of cardiovascular events in patients managed with an optimal evidence-based approach. Clinical studies have demonstrated a correlation between higher Lp(a) levels and several atherosclerotic diseases including ischemic heart disease, stroke, and degenerative calcific aortic stenosis. The threshold value of Lp(a) serum concentrations associated with a significantly increased cardiovascular risk is >125 nmol/L (50 mg/dL). Current available lipid-lowering drugs have modest-to-no impact on Lp(a) levels. Chronic inflammation is a further condition potentially implicated in residual cardiovascular risk. Consistent evidence has shown an increased risk of cardiovascular events in patients with high sensitivity C reactive protein (>2 mg/dL), an inflammation biomarker. A number of anti-inflammatory drugs have been investigated in patients with or at risk of cardiovascular disease. Of these, canakinumab and colchicine have been found to be associated with cardiovascular risk reduction. Ongoing research aimed at improving risk stratification on the basis of Lp(a) and vessel inflammation assessment may help refine patient management. Furthermore, the identification of these conditions as cardiovascular risk factors has led to increased investigation into diagnostic and therapeutic strategies targeting them in order to reduce atherosclerotic cardiovascular disease burden.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular preventioncolchicineinflammationlipoprotein (a)personalized medicine

Autor:innen und Institutionen

  • Clinical and Rehabilitation Unit, San Filippo Neri Hospital, ASL Rome 1, 00135 Rome, Italy.
  • ANMCO Research Center, Heart Care Foundation, 50121 Florence, Italy.
  • Cardiology Department, Hospital "F. Perinei" ASL, 70022 Altamura, Italy.
  • Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
  • Cardiology Unit, Cardiovascular Department, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.

ORCID-Profile: Stefania Angela Di Fusco, Aldo Pietro Maggioni, Pietro Scicchitano, Emilia D'Elia, Furio Colivicchi

Zitieren

APA

Di Fusco, S. A., Maggioni, A. P., Scicchitano, P., Zuin, M., D'Elia, E., & Colivicchi, F. (2023). Lipoprotein (a), Inflammation, and Atherosclerosis. Journal of Clinical Medicine, 12(7), 2529. https://doi.org/10.3390/jcm12072529

Vancouver

Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D'Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. Journal of Clinical Medicine. 2023;12(7):2529. doi:10.3390/jcm12072529

BibTeX
@article{DiFusco2023,
  author = {Di Fusco, Stefania Angela and Maggioni, Aldo Pietro and Scicchitano, Pietro and Zuin, Marco and D'Elia, Emilia and Colivicchi, Furio},
  title = {Lipoprotein (a), Inflammation, and Atherosclerosis},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {7},
  pages = {2529},
  doi = {10.3390/jcm12072529}
}
Kostenlos starten →